GemPharmatech

GemPharmatech is a rapidly growing, China-based preclinical CRO with a dominant position in the genetically engineered mouse model market. Its core assets are an extensive library of over 25,000 GEMMs and a high-capacity service platform capable of generating 6,000+ models annually. The company provides essential tools and services to pharmaceutical and biotechnology companies worldwide, accelerating drug discovery and development across numerous therapeutic areas including oncology, immunology, and metabolic diseases. Its business model is built on a mix of catalog model sales and high-value custom research services.

Integrated platform for generating and utilizing genetically engineered mouse models (GEMMs) using cutting-edge gene-editing (e.g., CRISPR). Includes a proprietary library of 25,000+ strains (KO/cKO, humanized, immunodeficient, germ-free), custom model generation services, and large-scale SPF breeding and preclinical testing infrastructure.

Competes with large, global preclinical CROs and model providers like The Jackson Laboratory (non-profit), Charles River Laboratories, and Taconic Biosciences, which have extensive catalogues and global distribution. Differentiation is achieved through scale (25,000+ models), cost-competitiveness, specialized immunodeficient strains (e.g., NCG), and a strong focus on the Chinese market while serving global clients.